Document is current
Any future updates will be listed below
-
Authors
Dong, Shuxian https://orcid.org/0000-0003-4725-8482
Wang, Qian
Kao, Yun-Ruei
Diaz, Antonio
Tasset, Inmaculada
Kaushik, Susmita https://orcid.org/0000-0002-6096-5387
Thiruthuvanathan, Victor
Zintiridou, Aliona
Nieves, Edward
Dzieciatkowska, Monika
Reisz, Julie A.
Gavathiotis, Evripidis https://orcid.org/0000-0001-6319-8331
D’Alessandro, Angelo https://orcid.org/0000-0002-2258-6490
Will, Britta https://orcid.org/0000-0002-9534-6690
Cuervo, Ana Maria https://orcid.org/0000-0002-0771-700X
- License Information
-
More Information
Article History
Received: 28 December 2019
Accepted: 9 December 2020
First Online: 13 January 2021
Competing interests
: A.M.C. and E.G. are cofounders of Selphagy Therapeutics (Boston, MA, USA). The CA compound is under the following patent: Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof. Gavathiotis, E., Cuervo. A. M., Xin, Q., Das, B. C. United States patent US9512092, granted 16 December 2016. All other authors declare no competing interests.
